The mitogen activated protein kinase (MAPK) signaling pathway or Ras/Raf/MEK/ERK pathway is one of the critical pathways involved in signal transduction, which results in the control of cell proliferation, survival, and differentiation
Till Now Four Mek Inhibitors Rametinib, Binimetinib, Selumetinib And Cobimetinib Are Approved By FDA
Global MEK Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 4 Drugs
- Approved MEK Drug Patent, Price & Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report: https://www.kuickresearch.com/report-mek-map-kinase-inhibitor-market-size-clinical-trials-report
The mitogen activated protein kinase (MAPK) signaling pathway or Ras/Raf/MEK/ERK pathway is one of the critical pathways involved in signal transduction, which results in the control of cell proliferation, survival, and differentiation. Studies have demonstrated that the signaling pathway plays a critical role in the development of various cancers including melanoma, non-small cell lung cancer, and several others. Therefore, targeting MAPK signaling pathway gained considerable interest among researchers as an alternative approach for the management of cancer. The extensive research and development activities in this sector have led to development of MEK inhibitors which work by inhibiting MAPK signaling pathway.
Mekinist (Trametinib) developed by GlaxoSmithKline was the first MEK inhibitor approved by regulatory bodies in 2014. The drug in combination with Tafinlar (dabrafenib) is indicated for the treatment of patients with unresectable/metastatic melanoma with BRAF V600E or V600K mutations. Apart from this, the drug is also used in treatment of anaplastic thyroid cancer and non-small cell lung cancer. The promising response of Mekinist in the global market has further led to entry of three other MEK inhibitors including Cotellic, Mektovi and Koselugo. The introduction of MEK inhibitors in the management of cancers has shown high adoption rates which can be justified by their robust sales.
Although systemic MEK inhibition suppresses tumor formation, it also causes significant adverse effects. To mitigate this challenge, NFlection Therapeutics developed NFX-179 which is topical MEK inhibitor. NFX-179 is a proprietary, metabolically labile, or “soft” compound — designed to concentrate key biological effects at the site of application while considerably reducing systemic exposure and thus side effects. The novel topical MEK inhibitor has shown promising response in preclinical models and is currently undergoing phase-I clinical trial. Apart from this, the global pipeline of MEK inhibitors is highly concentrated and consists of several potential candidates including AZD8330, E6201, CS3006, VS-6766, HL085, Pimacertib and Mirdametinib.
The accelerated sales of the drug and the significant advantages have drawn the attention of several researchers and pharmaceutical companies to invest in this sector. The extensive efforts by the researchers and the rising collaboration among the pharmaceutical giants are expected to drive the future of the market in coming years. For instance in 2021, Verastem Oncology announced a clinical trial collaboration with Amgen to evaluate the combination of VS-6766, Verastem Oncology’s investigational dual RAF/MEK inhibitor, with Amgen’s KRAS G12C inhibitor Lumakras (sotorasib) in KRAS G12C-mutant non-small cell lung cancer (NSCLC). Apart from this, Verastem Oncology also collaborated with Mirati Therapeutics to evaluate Adagrasib in combination with VS-6766 in KRAS G12C-mutant non-small cell lung cancer.
The advent of MEK inhibitor in the management of cancer has greatly transformed the cancer therapeutics market. In a short span of time, MEK inhibitory drugs have contributed to a significant share in the cancer therapeutics market owing to their high specificity and target ability towards cancer cell. Unlike conventional cancer therapies, the novel class of MEK inhibitors is not associated with any adverse side-effects and does not hamper the quality of life of patients, which further propel the growth of market. Moreover, there will no competition from generic drugs during the forecast period, which further boost their sales at a global level, thus driving the growth of market.
As per our report findings, the global MEK inhibitor market is expected to surpass US$ 3 Billion by 2026. Several factors including increasing prevalence of cancer, unmet need of targeted therapy, crowded pipeline, and huge investments by pharmaceutical giants. In addition, development of favorable reimbursement policies in region like US and Europe also boosts the uptake of novel MEK inhibitors in the market. The global MEK inhibitor market is highly competitive and consists of several key players including Roche, Pfizer, AstraZeneca, Novartis, Cstone Therapeutics, and Ono Pharmaceuticals.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366